**This event has run**

Register interest for 2023

7:20 am Registration & Morning Networking Coffee

8:35 am Chairperson’s Opening Remarks

Navigating the Future Outlook of Successful mRNA-Based Vaccines and Therapeutics

8:45 am mRNA-1273 (Spikevax) – The Past, Present, & Future?

Synopsis

  • Adult vaccine development
  • Pediatric vaccine development
  • Variant vaccine development

9:15 am Pharma Leaders Fireside Discussion

  • Jacob Becraft Co-Founder & CEO, Strand Therapeutics
  • Kathy Fernando VP, Head of Worldwide Research, Development and Medical Operations; Head of mRNA Scientific Planning, Pfizer
  • Regis Gervier Global Head mRNA Center of Excellence , Sanofi
  • Michelle Lynn Hall Associate Vice President – Genetic Medicine, Eli Lilly & Company

Synopsis

With the next wave of mRNA on the rise and with large pharma who were involved in prepandemic now having a validated platform in their hands to develop new therapeutics and vaccines, this leads to the inevitable question: What comes next? It is now important to realize the opportunities of such mRNA- based therapeutic applications, the opportunities to develop global partnerships and collaboration as we hear from leading experts on the future of this technology

10:00 am Chromatographic Tools in an mRNA process: From Analytics to Purification

Synopsis

  • Overcoming technical challenges at all stages: plasmid production and linearisation, in vitro transcription (IVT), purification of mRNA and production of lipid nanoparticles (LNP). In addition, improving process economics will further enable the use of mRNA therapeutics in low-income countries
  • Rapid, at-line analytical technologies can be used to monitor IVT reactions, and to optimise process parameters. Analytical HPLC with CIMac PrimaS™ can separate the constituents of the reaction, including the capping reagent, nucleotides, plasmid DNA, and mRNA within a 3-minute analysis time
  • Chromatography using multimodal ligands is well-established to capture non-polyadenylated RNA from IVT processes. CIM® PrimaS can separate RNA from contaminants in an IVT reaction. Multimodal chromatography is explored here as a capture method for mRNA purification

10:30 am Morning Structured Networking

1:00 pm Networking Lunch Break

4:00 pm Afternoon Networking Break

4:30 pm Overcoming the DNA Bottleneck: Powering mRNA Therapies into the Future with LinearDNA™

  • James A. Hayward Chief Executive Officer, LineaRx, an Applied DNA Sciences company

Synopsis

  • The LinearDNA Platform – Supplanting plasmid-DNA with enzymatically produced DNA
  • A Better IVT Template – Logic and data supporting LinearDNA platform speed and ease of DNA manufacturing
  • A Better IVT Template – Logic and data supporting the ability to produce RNA therapeutics from LinearDNA IVT template

5:00 pm Diversity, Equity & Inclusion Panel Discussion: Prioritizing Diversity, Equity & Inclusion in the mRNA Industry

  • Rachel Groppo Director - Replicon Team Leader, The Janssen Pharmaceutical Companies of Johnson & Johnson
  • Linda Marban CEO, Capricor Therapeutics
  • Kalina Paunovska Co-Founder, Nava Therapeutics, Dahlman Lab
  • Jane True VP - mRNA Commercial Development, Pfizer

Synopsis

  • What impacts are there on talent strategy in organizations today?
  • What is something actionable people can do today to make the scientific field more inclusive?
  • What developments and practices have organizations made or put in place that other leaders should consider adopting?

5:30 pm An Overview of the mRNA Landscape & Future Directions

  • Will Savill RNA Account Manager , Beacon Targeted Therapies

Synopsis

  • A brief overview of the RNA drug and trial landscape
  • An in-depth analysis of the mRNA space and its development
  • A look into the future of mRNA and emerging trends

6:00 pm Chair’s Closing Remarks

6:15 pm Poster Session & Drinks Reception

End of Conference Day 1